- RecruitingPHASE1, PHASE2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
This study is testing a new drug, neladalkib, for advanced cancers that have a specific genetic change called ALK rearrangement. It's looking at how safe the drug is and if it shrinks tumours in people with certain types of lung cancer and other solid tumours.
For: Locally Advanced Solid Tumor · Metastatic Solid TumorUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
This study is looking into a new medicine, ODM-208, for men with prostate cancer that has spread and is resistant to standard treatments. It aims to see how safe the drug is, what side effects it might cause, and how the body handles it.
For: Prostate Cancer MetastaticUnited States · Finland · France - Active not recruitingPHASE2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This study is testing a new drug, PF-07220060, for people with advanced cancers like breast, prostate, and lung cancer. Researchers want to see if it's safe and how it works, both by itself and with other cancer medicines.
For: Liposarcoma · Prostate Cancer · Breast NeoplasmsUnited States · Argentina · China - RecruitingPHASE1
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
This study is looking at how a new medicine, Afimkibart, affects how your body processes other common medicines in people with active ulcerative colitis. We want to see if it changes how your body uses them.
For: Active Ulcerative ColitisUnited States · Germany · United Kingdom - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
This study looks at two drug combinations, inavolisib with fulvestrant, and alpelisib with fulvestrant, for advanced breast cancer that has specific genetic changes and has already been treated with certain therapies. It aims to see which combination works better and is safer.
For: Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
This study is for adults with advanced cancer that has a specific KRAS gene change. It tests new medicines, BI 1823911 alone and with BI 1701963, to see if they can shrink tumours. Currently, there are no other successful treatments.
For: Solid Tumors, KRAS MutationUnited States · Belgium · Spain - RecruitingPHASE1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
This study is testing a new medicine, PF-07799933, for advanced cancers with a specific gene change (BRAF alterations). It aims to see how safe and effective it is, sometimes combined with other medicines, for people when usual treatments haven't worked.
For: Melanoma · Non-Small-Cell Lung Cancer · Thyroid CancerUnited States · Canada · Israel - RecruitingPHASE3
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
This study looks into new ways to treat advanced stomach and gut cancers called GIST. It compares a new drug called CGT9486 (bezuclastinib) combined with an existing drug, sunitinib, against sunitinib alone, to see which works better for patients who haven't responded well to other treatments.
For: Advanced Gastrointestinal Stromal Tumors · Metastatic CancerUnited States · Argentina · Australia - RecruitingPHASE3
Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia
This study looks at whether calming medicines given before surgery help children aged 7-18 feel better. Researchers want to see if these medicines, Midazolam or Dexmedetomidine, reduce anxiety without causing new problems after an operation.
For: AnesthesiaFrance - Active not recruitingPHASE2
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
This study looks at a new drug, erdafitinib, for people with a type of bladder cancer called urothelial cancer that has spread or can't be removed by surgery. It aims to see how well it works and if it's safe, specifically for those with certain genetic changes in their cancer.
For: Urothelial CancerUnited States · Austria · Belgium - RecruitingPHASE1
A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and Women
This study is testing a new medicine, BI 3031185, to see how safe it is and how the body handles different doses. It involves healthy men and women.
For: HealthyGermany - RecruitingPHASE3
Efficacy of Dexmedetomidine Versus Midazolam Sedation on Extubation Time in Mechanically Ventilated Preterm Infants
This study compares two sedatives, dexmedetomidine and midazolam, for very premature babies on breathing machines. We want to see if one helps babies come off the machine sooner and recover better.
For: PreTerm Neonate · Sedation for Invasive Mechanical Ventilation · Very Preterm Neonates With Sedation for Invasive Mechanical VentilationFrance - Active not recruitingPHASE1, PHASE2
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
This study is testing a new medicine called sotorasib for people with specific advanced cancers carrying a KRAS p.G12C gene change. Researchers want to see if it's safe, how much to give, and if it helps shrink tumours. It's an early-stage trial looking for better cancer treatments.
For: KRAS p.G12C Mutant Advanced Solid TumorsUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
This study is testing a new drug called ziftomenib for people with a type of blood cancer called acute myeloid leukaemia (AML) that has come back or not responded to previous treatments. It's the first time this drug is being used in people.
For: Advanced Malignant Neoplasm · Acute Myeloid Leukemia · Mixed Lineage LeukemiaUnited States · Belgium · Canada